QuidelOrtho Corporation
NASDAQ:QDEL · NASDAQ Global Select
+$0.09 today
Vol 2.04M · Avg 2.35M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-58.9%
avg -0.2%
ROIC
-18.3%
avg 6.3%
ROA
-19.6%
avg 3.5%
Analysis
ROIC is currently the strongest return metric at -18.3% versus its period average of 6.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph Busky | Chief Financial Officer | $2.64M | — | 58 | $18,705.00 | 0.03% |
Brian J. Blaser | President, Chief Executive Officer & Director | $2.29M | — | 61 | $45,901.00 | 0.07% |
Jonathan Siegrist | Executive Vice President of Research & Development and Chief Technology Officer | $1.29M | — | 44 | $36,152.00 | 0.05% |
Nathaniel Sisitsky | Chief Legal Officer & Corporate Secretary | $1.21M | — | 52 | $73,435.00 | 0.11% |
Philip McLellan | Chief Operations Officer | $1.02M | — | 56 | $23,196.00 | 0.03% |
Juliet C. Cunningham | Vice President of Investor Relations | — | — | — | — | — |
Lisa S. Hayes | Vice President of Global Marketing & Corporate Communications | — | — | — | $17,944.00 | 0.03% |
Ronald Lee Bowman | Chief Human Resources Officer | — | — | 47 | $36,150.00 | 0.05% |
Audra Jones | Senior VP & Head of North America | — | — | — | — | — |
Iris Lin | Head of JAPAC (Japan, ASPAC & China) | — | — | — | — | — |
Andrew Corkum | Senior VP and Head of EMEA & LATAM | — | — | — | — | — |
Bryan Hanson | Executive VP of Global Portfolio Management and Marketing | — | — | 46 | $4,598.00 | <0.01% |
Erich Wolff | Executive Vice President of Strategy & Corporate Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$1.25M
Sells
1
$111,965.48
Net Sentiment
+$1.14M
Net buying
Most Active
Busky Joseph M.
2 transactions
Analysis
Insiders reported 8 buys worth $1.25M and 1 sells worth $111,965.48 over the last 12 months. That adds up to net buying of $1.14M. Busky Joseph M. was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +8.0% | +19.5% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | -32.4% | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +8.0% over three years. Forward estimates point to Revenue at +19.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$5.35B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.90B
National HealthCare Corporation
AMEX:NHC
$3.03B
uniQure N.V.
NASDAQ:QURE
$2.98B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.61B
LeMaitre Vascular, Inc.
NASDAQ:LMAT
$2.13B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.05B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.49B
AtriCure, Inc.
NASDAQ:ATRC
$1.41B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Who manages QDEL?
QuidelOrtho Corporation (QDEL) lists 13 active executives. The top listed executive is Juliet C. Cunningham, Vice President of Investor Relations.
Are QDEL insiders buying or selling?
Recent insider activity shows net buying of $4.72M.
Explore More
Continue the stock analysis
Jump to another research area for this company.